View Past PerformanceVimab Group バランスシートの健全性財務の健全性 基準チェック /26Vimab Groupの総株主資本はSEK14.2M 、総負債はSEK104.2Mで、負債比率は732.7%となります。総資産と総負債はそれぞれSEK257.6MとSEK243.4Mです。主要情報732.65%負債資本比率SEK 104.23m負債インタレスト・カバレッジ・レシオn/a現金SEK 15.81mエクイティSEK 14.23m負債合計SEK 243.38m総資産SEK 257.60m財務の健全性に関する最新情報分析記事 • Mar 14We Think Vimab Group (STO:VIMAB) Is Taking Some Risk With Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...すべての更新を表示Recent updatesNew Risk • Jun 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 81% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr56m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr137.9m market cap, or US$14.8m).Reported Earnings • May 19First quarter 2026 earnings released: kr0.50 loss per share (vs kr1.22 loss in 1Q 2025)First quarter 2026 results: kr0.50 loss per share (improved from kr1.22 loss in 1Q 2025). Revenue: kr70.4m (up 27% from 1Q 2025). Net loss: kr21.8m (loss narrowed 29% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings.お知らせ • May 13Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026, at 10:00 W. Europe Standard Time. Location: wigge & partners law kb`s premises, at birger jarlsgatan 25 in, stockholm SwedenReported Earnings • Mar 17Full year 2025 earnings released: kr3.90 loss per share (vs kr3.31 loss in FY 2024)Full year 2025 results: kr3.90 loss per share (further deteriorated from kr3.31 loss in FY 2024). Revenue: kr328.6m (up 1.0% from FY 2024). Net loss: kr101.7m (loss widened 32% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year whereas the company’s share price has fallen by 41% per year.分析記事 • Jan 14Investors Give Vimab Group AB (publ) (STO:VIMAB) Shares A 26% HidingTo the annoyance of some shareholders, Vimab Group AB (publ) ( STO:VIMAB ) shares are down a considerable 26% in the...New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr89.5m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (kr89.5m market cap, or US$9.74m). Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change).お知らせ • Dec 03Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million.Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,545,158 Price\Range: SEK 4.8 Transaction Features: Rights OfferingNew Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr52m free cash flow). Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (kr110.4m market cap, or US$11.7m).Reported Earnings • Nov 10Third quarter 2025 earnings released: kr0.20 loss per share (vs kr0.49 loss in 3Q 2024)Third quarter 2025 results: kr0.20 loss per share (improved from kr0.49 loss in 3Q 2024). Revenue: kr94.4m (up 24% from 3Q 2024). Net loss: kr5.03m (loss narrowed 57% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.分析記事 • Sep 10It's A Story Of Risk Vs Reward With Vimab Group AB (publ) (STO:VIMAB)With a median price-to-sales (or "P/S") ratio of close to 0.6x in the Professional Services industry in Sweden, you...Reported Earnings • Aug 31Second quarter 2025 earnings released: kr0.40 loss per share (vs kr0.16 loss in 2Q 2024)Second quarter 2025 results: kr0.40 loss per share (further deteriorated from kr0.16 loss in 2Q 2024). Revenue: kr84.6m (down 12% from 2Q 2024). Net loss: kr11.2m (loss widened 208% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 6% per year.New Risk • Jun 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.8m free cash flow). Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (kr211.3m market cap, or US$21.9m).Reported Earnings • May 22First quarter 2025 earnings released: kr1.20 loss per share (vs kr0.80 loss in 1Q 2024)First quarter 2025 results: kr1.20 loss per share (further deteriorated from kr0.80 loss in 1Q 2024). Revenue: kr56.7m (down 16% from 1Q 2024). Net loss: kr30.9m (loss widened 72% from 1Q 2024).お知らせ • May 14Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025, at 10:00 W. Europe Standard Time. Location: at wigge & partners advokat kb`s premises, at birger jarlsgatan 25, stockholm SwedenReported Earnings • Mar 13Full year 2024 earnings released: kr3.60 loss per share (vs kr0.20 loss in FY 2023)Full year 2024 results: kr3.60 loss per share (further deteriorated from kr0.20 loss in FY 2023). Revenue: kr330.2m (down 3.5% from FY 2023). Net loss: kr76.9m (loss widened kr72.7m from FY 2023).New Risk • Mar 13New major risk - Revenue and earnings growthEarnings have declined by 2.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr173.3m market cap, or US$17.0m).分析記事 • Feb 16Take Care Before Jumping Onto Vimab Group AB (publ) (STO:VIMAB) Even Though It's 26% CheaperVimab Group AB (publ) ( STO:VIMAB ) shares have retraced a considerable 26% in the last month, reversing a fair amount...分析記事 • Dec 22Vimab Group AB (publ) (STO:VIMAB) Soars 29% But It's A Story Of Risk Vs RewardVimab Group AB (publ) ( STO:VIMAB ) shares have had a really impressive month, gaining 29% after a shaky period...お知らせ • Dec 21An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million.An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million on December 19, 2024. The divestment is intended to take place for a purchase price of approximately SEK 200 million on a cash and debt-free basis, which will be paid in cash when the shares are acquired. Net sales for Vimab AB in the financial year 2023 amounted to approximately SEK 200.1 million with an EBITDA result of approximately SEK 23.1 million, which corresponds to an EBITDA margin of approximately 11.5 percent. The divestiture is conditional on the Stakeholder's due diligence and the parties agreeing to enter into a share transfer agreement. Signing of the share transfer agreement and access is planned for the first quarter of 2025. Mangold Fondkommission AB acted as financial advisor for Vimab Group AB. Wigge & Partners Advokat Kb acted as legal advisor for Vimab Group AB.分析記事 • Nov 06Vimab Group AB (publ)'s (STO:VIMAB) Shares Not Telling The Full StoryThere wouldn't be many who think Vimab Group AB (publ)'s ( STO:VIMAB ) price-to-sales (or "P/S") ratio of 0.7x is worth...New Risk • Nov 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.8m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (kr259.6m market cap, or US$24.2m).Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.36 profit in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (down from kr0.36 profit in 2Q 2023). Revenue: kr96.7m (up 8.2% from 2Q 2023). Net loss: kr3.63m (down 150% from profit in 2Q 2023).Reported Earnings • May 09First quarter 2024 earnings released: kr0.80 loss per share (vs kr0.53 loss in 1Q 2023)First quarter 2024 results: kr0.80 loss per share (further deteriorated from kr0.53 loss in 1Q 2023). Revenue: kr68.5m (up 72% from 1Q 2023). Net loss: kr17.9m (loss widened 72% from 1Q 2023).お知らせ • May 08Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024, at 10:00 W. Europe Standard Time. Location: wigge & partners advokat kb`s, premises at birger jarlsgatan 25, stockholm Sweden分析記事 • Mar 14We Think Vimab Group (STO:VIMAB) Is Taking Some Risk With Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Mar 13Full year 2023 earnings released: kr0.30 loss per share (vs kr3.44 loss in FY 2022)Full year 2023 results: kr0.30 loss per share (improved from kr3.44 loss in FY 2022). Revenue: kr347.8m (up 53% from FY 2022). Net loss: kr4.26m (loss narrowed 88% from FY 2022).Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: kr0.20 (vs kr0.49 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.20 (up from kr0.49 loss in 3Q 2022). Revenue: kr99.7m (up 69% from 3Q 2022). Net income: kr4.86m (up kr12.0m from 3Q 2022). Profit margin: 4.9% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue.財務状況分析短期負債: VIMABの 短期資産 ( SEK168.6M ) は 短期負債 ( SEK236.2M ) をカバーしていません。長期負債: VIMABの短期資産 ( SEK168.6M ) が 長期負債 ( SEK7.1M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: VIMABの 純負債対資本比率 ( 621.5% ) は 高い と見なされます。負債の削減: VIMABは 5 年前には株主資本がマイナスでしたが、現在はプラスになっており、改善されています。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: VIMABは、現在の フリーキャッシュフロー に基づくと、キャッシュランウェイ が 1 年未満です。キャッシュランウェイの予測: VIMABは、フリーキャッシュフローが毎年56.9 % の歴史的率で減少し続ける場合、キャッシュランウェイが 1 年未満になります。健全な企業の発掘7D1Y7D1Y7D1YCommercial-services 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 15:43終値2026/06/16 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vimab Group AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • Mar 14We Think Vimab Group (STO:VIMAB) Is Taking Some Risk With Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Jun 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 81% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr56m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr137.9m market cap, or US$14.8m).
Reported Earnings • May 19First quarter 2026 earnings released: kr0.50 loss per share (vs kr1.22 loss in 1Q 2025)First quarter 2026 results: kr0.50 loss per share (improved from kr1.22 loss in 1Q 2025). Revenue: kr70.4m (up 27% from 1Q 2025). Net loss: kr21.8m (loss narrowed 29% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings.
お知らせ • May 13Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026, at 10:00 W. Europe Standard Time. Location: wigge & partners law kb`s premises, at birger jarlsgatan 25 in, stockholm Sweden
Reported Earnings • Mar 17Full year 2025 earnings released: kr3.90 loss per share (vs kr3.31 loss in FY 2024)Full year 2025 results: kr3.90 loss per share (further deteriorated from kr3.31 loss in FY 2024). Revenue: kr328.6m (up 1.0% from FY 2024). Net loss: kr101.7m (loss widened 32% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year whereas the company’s share price has fallen by 41% per year.
分析記事 • Jan 14Investors Give Vimab Group AB (publ) (STO:VIMAB) Shares A 26% HidingTo the annoyance of some shareholders, Vimab Group AB (publ) ( STO:VIMAB ) shares are down a considerable 26% in the...
New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr89.5m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (kr89.5m market cap, or US$9.74m). Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change).
お知らせ • Dec 03Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million.Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,545,158 Price\Range: SEK 4.8 Transaction Features: Rights Offering
New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr52m free cash flow). Negative equity (-kr7.1m). Earnings have declined by 30% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (kr110.4m market cap, or US$11.7m).
Reported Earnings • Nov 10Third quarter 2025 earnings released: kr0.20 loss per share (vs kr0.49 loss in 3Q 2024)Third quarter 2025 results: kr0.20 loss per share (improved from kr0.49 loss in 3Q 2024). Revenue: kr94.4m (up 24% from 3Q 2024). Net loss: kr5.03m (loss narrowed 57% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.
分析記事 • Sep 10It's A Story Of Risk Vs Reward With Vimab Group AB (publ) (STO:VIMAB)With a median price-to-sales (or "P/S") ratio of close to 0.6x in the Professional Services industry in Sweden, you...
Reported Earnings • Aug 31Second quarter 2025 earnings released: kr0.40 loss per share (vs kr0.16 loss in 2Q 2024)Second quarter 2025 results: kr0.40 loss per share (further deteriorated from kr0.16 loss in 2Q 2024). Revenue: kr84.6m (down 12% from 2Q 2024). Net loss: kr11.2m (loss widened 208% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 6% per year.
New Risk • Jun 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.8m free cash flow). Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (kr211.3m market cap, or US$21.9m).
Reported Earnings • May 22First quarter 2025 earnings released: kr1.20 loss per share (vs kr0.80 loss in 1Q 2024)First quarter 2025 results: kr1.20 loss per share (further deteriorated from kr0.80 loss in 1Q 2024). Revenue: kr56.7m (down 16% from 1Q 2024). Net loss: kr30.9m (loss widened 72% from 1Q 2024).
お知らせ • May 14Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025, at 10:00 W. Europe Standard Time. Location: at wigge & partners advokat kb`s premises, at birger jarlsgatan 25, stockholm Sweden
Reported Earnings • Mar 13Full year 2024 earnings released: kr3.60 loss per share (vs kr0.20 loss in FY 2023)Full year 2024 results: kr3.60 loss per share (further deteriorated from kr0.20 loss in FY 2023). Revenue: kr330.2m (down 3.5% from FY 2023). Net loss: kr76.9m (loss widened kr72.7m from FY 2023).
New Risk • Mar 13New major risk - Revenue and earnings growthEarnings have declined by 2.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr173.3m market cap, or US$17.0m).
分析記事 • Feb 16Take Care Before Jumping Onto Vimab Group AB (publ) (STO:VIMAB) Even Though It's 26% CheaperVimab Group AB (publ) ( STO:VIMAB ) shares have retraced a considerable 26% in the last month, reversing a fair amount...
分析記事 • Dec 22Vimab Group AB (publ) (STO:VIMAB) Soars 29% But It's A Story Of Risk Vs RewardVimab Group AB (publ) ( STO:VIMAB ) shares have had a really impressive month, gaining 29% after a shaky period...
お知らせ • Dec 21An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million.An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million on December 19, 2024. The divestment is intended to take place for a purchase price of approximately SEK 200 million on a cash and debt-free basis, which will be paid in cash when the shares are acquired. Net sales for Vimab AB in the financial year 2023 amounted to approximately SEK 200.1 million with an EBITDA result of approximately SEK 23.1 million, which corresponds to an EBITDA margin of approximately 11.5 percent. The divestiture is conditional on the Stakeholder's due diligence and the parties agreeing to enter into a share transfer agreement. Signing of the share transfer agreement and access is planned for the first quarter of 2025. Mangold Fondkommission AB acted as financial advisor for Vimab Group AB. Wigge & Partners Advokat Kb acted as legal advisor for Vimab Group AB.
分析記事 • Nov 06Vimab Group AB (publ)'s (STO:VIMAB) Shares Not Telling The Full StoryThere wouldn't be many who think Vimab Group AB (publ)'s ( STO:VIMAB ) price-to-sales (or "P/S") ratio of 0.7x is worth...
New Risk • Nov 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.8m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (kr259.6m market cap, or US$24.2m).
Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.36 profit in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (down from kr0.36 profit in 2Q 2023). Revenue: kr96.7m (up 8.2% from 2Q 2023). Net loss: kr3.63m (down 150% from profit in 2Q 2023).
Reported Earnings • May 09First quarter 2024 earnings released: kr0.80 loss per share (vs kr0.53 loss in 1Q 2023)First quarter 2024 results: kr0.80 loss per share (further deteriorated from kr0.53 loss in 1Q 2023). Revenue: kr68.5m (up 72% from 1Q 2023). Net loss: kr17.9m (loss widened 72% from 1Q 2023).
お知らせ • May 08Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024, at 10:00 W. Europe Standard Time. Location: wigge & partners advokat kb`s, premises at birger jarlsgatan 25, stockholm Sweden
分析記事 • Mar 14We Think Vimab Group (STO:VIMAB) Is Taking Some Risk With Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Mar 13Full year 2023 earnings released: kr0.30 loss per share (vs kr3.44 loss in FY 2022)Full year 2023 results: kr0.30 loss per share (improved from kr3.44 loss in FY 2022). Revenue: kr347.8m (up 53% from FY 2022). Net loss: kr4.26m (loss narrowed 88% from FY 2022).
Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: kr0.20 (vs kr0.49 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.20 (up from kr0.49 loss in 3Q 2022). Revenue: kr99.7m (up 69% from 3Q 2022). Net income: kr4.86m (up kr12.0m from 3Q 2022). Profit margin: 4.9% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue.